Powered by: Motilal Oswal

News

Indian pharma industry is likely to grow at 9-11% in FY26 : Motilal Oswal Wealth Management According to Motilal Oswal Wealth Management Ltd., the Indian pharma industry is likely to grow at 9-11% in FY26 (as per Crisil Report), led by price hike and new launches in domestic market and rise in export demand from regulated markets. The Government of India has introduced PLI scheme for pharma industry to promote Make-in-India, wherein ~18-20% of imported drugs can be manufactured locally. For hospitals, we expect profitability to improve due to addition of beds, increase in oc...
Indian pharma industry is likely to grow at 9-11% in FY26 : Motilal Oswal Wealth Management
Indian pharma industry is likely to grow at 9-11% in FY26 : Motilal Oswal Wealth Management
Source: Motilal Oswal Wealth Management
2024-12-24 02:01:51 pm
Buy Mankind Pharma Ltd For Target Rs.3,140 By Motilal Oswal Financial Services Ltd Superior execution in consumer wellness/exports drives beat on 2Q estimates Integration of BSV under way * Mankind Pharma (MANKIND) delivered better-than-expected 2QFY25 performance, fueled by a strong revival in growth of the consumer business and continued growth momentum in the exports business. * MANKIND continues to deliver a better growth rate than the industry in the Rx-prescription business, supported by a niche portfolio and superior execution in chronic therapies....
Buy Mankind Pharma Ltd For Target Rs.3,140 By Motilal Oswal Financial Services Ltd
Buy Mankind Pharma Ltd For Target Rs.3,140 By Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services Ltd
2024-11-19 02:42:14 pm
Mankind Pharma completes acquisition of BSV for Rs 13,768 crore Mankind Pharma on Wednesday said it has completed the acquisition of Bharat Serums and Vaccines Limited (BSV) for Rs 13,768 crore.  The acquisition will position Mankind Pharma as a market leader in the Indian women's health and fertility drug market, alongside access to other high entry barrier products in critical care segment with established complex R&D tech platforms, it said in a statement. Their established specialty R&D tech platforms with complex portfo...
Mankind Pharma completes acquisition of BSV for Rs 13,768 crore
Mankind Pharma completes acquisition of BSV for Rs 13,768 crore
Source: IANS
2024-10-24 09:22:03 am
Buy Mankind Pharma Ltd For Target Rs. 2,760 By Motilal Oswal Financial Services Ltd Improvising the base; adding new avenues for growth * Following our Initiating Coverage on Mankind Pharma (MANKIND), we have highlighted certain key aspects from the recently released annual report. * MANKIND has a strategic roadmap for growth through expansion in high entry barrier innovative product launches in the chronic/consumer segment and other adjacencies, transitioning from sexual wellness to consumer wellness in the over-thecounter (OTC) space. * During FY22-24, its strateg...
Buy Mankind Pharma Ltd For Target Rs. 2,760 By Motilal Oswal Financial Services Ltd
Buy Mankind Pharma Ltd For Target Rs. 2,760 By Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services Ltd
2024-09-09 03:54:08 pm
Buy Mankind Pharma Ltd Target Rs.2,760 By Motilal Oswal Financial Services Ltd Improvising the base; adding new avenues for growth * Following our Initiating Coverage on Mankind Pharma (MANKIND), we have highlighted certain key aspects from the recently released annual report. * MANKIND has a strategic roadmap for growth through expansion in high entry barrier innovative product launches in the chronic/consumer segment and other adjacencies, transitioning from sexual wellness to consumer wellness in the over-thecounter (OTC) space. * During FY22-24, its strat...
Buy Mankind Pharma Ltd Target Rs.2,760 By Motilal Oswal Financial Services Ltd
Buy Mankind Pharma Ltd Target Rs.2,760 By Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services Ltd Ltd
2024-09-02 05:55:51 pm
Buy Mankind Pharma Ltd Target Rs.2,760 By Motilal Oswal Financial Services Ltd Improvising the base; adding new avenues for growth * Following our Initiating Coverage on Mankind Pharma (MANKIND), we have highlighted certain key aspects from the recently released annual report. * MANKIND has a strategic roadmap for growth through expansion in high entry barrier innovative product launches in the chronic/consumer segment and other adjacencies, transitioning from sexual wellness to consumer wellness in the over-thecounter (OTC) space. * During FY22-24, its strat...
Buy Mankind Pharma Ltd Target Rs.2,760 By Motilal Oswal Financial Services Ltd
Buy Mankind Pharma Ltd Target Rs.2,760 By Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services Ltd Ltd
2024-09-02 11:20:54 am
Buy Mankind Pharma Ltd For Target Rs. 2,760 By Motilal Oswal Financial Services Ltd Improvising the base; adding new avenues for growth * Following our Initiating Coverage on Mankind Pharma (MANKIND), we have highlighted certain key aspects from the recently released annual report. * MANKIND has a strategic roadmap for growth through expansion in high entry barrier innovative product launches in the chronic/consumer segment and other adjacencies, transitioning from sexual wellness to consumer wellness in the over-thecounter (OTC) space. * During FY22-24, its strateg...
Buy Mankind Pharma Ltd For Target Rs. 2,760 By Motilal Oswal Financial Services Ltd
Buy Mankind Pharma Ltd For Target Rs. 2,760 By Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services Ltd
2024-08-24 09:24:15 am
Indian startups secure $395 million this week, a massive 350 pc jump  Riding on overall economic growth, Indian startups raised more than $395 million in at least 20 deals this week, a massive about 350 per cent jump from $113 million secured last week in 22 deals.  Hospitality and travel-tech company Oyo led the funding ecosystem with raising Rs 1,457 crore (nearly $175 million) in a Series G round from investors like InCred Wealth, Patient Capital, J&A Partners, the family office of Mankind Pharma promoters and ASK Financial Holdings, am...
Indian startups secure $395 million this week, a massive 350 pc jump
Indian startups secure $395 million this week, a massive 350 pc jump
Source: IANS
2024-08-17 02:12:43 pm
Buy Mankind Pharma Ltd For Target Rs.2,650 By Motilal Oswal Financial Services Unlocking new vertical through BSV acquisition Aim to be EPS-accretive from second year after deal closure * Mankind Pharma has agreed to acquire Bharat Serum Vaccines (BSV) for EV of INR136b, implying EV/EBITDA of 28x/22-23x on FY24/FY25 basis. * This acquisition not only expands Mankind’s niche portfolio, but also provides a specialty R&D tech platform, in-house complex manufacturing capabilities and strong institutional reach. * Considering access to a high-entry barr...
Buy Mankind Pharma Ltd For Target Rs.2,650 By Motilal Oswal Financial Services
Buy Mankind Pharma Ltd For Target Rs.2,650 By Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
2024-08-01 03:44:16 pm
Buy Mankind Pharma Ltd For Target Rs.2,650 By Motilal Oswal Financial Services Disruptor with a dose of care * In a span of 30 years, Mankind Pharma (MANKIND) has built a robust domestic formulation (DF) franchise and become the fourth largest player by market share. * Contrary to common wisdom, MANKIND has followed a disruptive strategy to establish its DF business by approaching customers and influencers in tier II and below cities, becoming the industry leader in terms of the number of prescriptions. * It has diversified its portfolio in terms of both therap...
Buy Mankind Pharma Ltd For Target Rs.2,650 By Motilal Oswal Financial Services
Buy Mankind Pharma Ltd For Target Rs.2,650 By Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services
2024-07-08 03:15:01 pm
Buy Mankind Pharma Ltd For Target Rs.2,650 By Motilal Oswal Financial Services Disruptor with a dose of care * In a span of 30 years, Mankind Pharma (MANKIND) has built a robust domestic formulation (DF) franchise and become the fourth largest player by market share. * Contrary to common wisdom, MANKIND has followed a disruptive strategy to establish its DF business by approaching customers and influencers in tier II and below cities, becoming the industry leader in terms of the number of prescriptions. * It has diversified its portfolio in terms of both thera...
Buy Mankind Pharma Ltd For Target Rs.2,650 By Motilal Oswal Financial Services
Buy Mankind Pharma Ltd For Target Rs.2,650 By Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services
2024-07-07 02:50:32 pm
India`s Mankind Pharma`s Q4 profit jumps on strength in chronic drugs segment Indian pharmaceutical company Mankind Pharma posted a more than 65% rise in its fourth-quarter profit on Wednesday, helped by strong domestic demand in its chronic drugs segment. The company also approved a fundraise of up to 75 billion rupees or an equivalent amount via issuance of shares under qualified institutional placement, it said in an exchange filing. Mankind, which makes acute and chronic therapeutics, including anti-infectives and anti-diabetics, posted consolidated profit at...
India`s Mankind Pharma`s Q4 profit jumps on strength in chronic drugs segment
India`s Mankind Pharma`s Q4 profit jumps on strength in chronic drugs segment
Source: Reuters
2024-05-16 10:56:33 am
Public equity fundraising increased by a huge 142 pc to Rs 1.86 lakh crore Overall public equity fundraising increased by a huge 142 per cent to Rs 1.86 lakh crore in 2023-24 from Rs 76,911 crore in 2022-23. Pranav Haldea, Managing Director, Prime Database, said 76 Indian corporates raised Rs 61,915 crore through main board IPOs in financial year 2023-24, 19 per cent higher than the Rs 52,116 crore mobilised by 37 IPOs in 2022-23. The largest IPO in 2023-24 was from Mankind Pharma (Rs 4,326 crore). This was followed by Tata Technologies (Rs 3,043 crore) and JS...
Public equity fundraising increased by a huge 142 pc to Rs 1.86 lakh crore
Public equity fundraising increased by a huge 142 pc to Rs 1.86 lakh crore
Source: IANS
2024-03-26 04:43:01 pm
Mankind Pharma inches up on inking pact with AstraZeneca Pharma India Mankind Pharma is currently trading at Rs. 2165.60, up by 3.30 points or 0.15% from its previous closing of Rs. 2162.30 on the BSE. The scrip opened at Rs. 2156.80 and has touched a high and low of Rs. 2195.95 and Rs. 2154.60 respectively. So far 1732 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 2297.00 on 08-Feb-2024 and a 52 week low of Rs. 1240.75 on 22-May-2023. Last one week high and low of the scrip sto...
Mankind Pharma inches up on inking pact with AstraZeneca Pharma India
Mankind Pharma inches up on inking pact with AstraZeneca Pharma India
Source: Accord Fintech
2024-03-12 10:21:41 am
Mankind Pharma rises on making investment in Actimed Therapeutics Mankind Pharma is currently trading at Rs. 1895.00, up by 7.20 points or 0.38% from its previous closing of Rs. 1887.80 on the BSE. The scrip opened at Rs. 1925.60 and has touched a high and low of Rs. 1925.60 and Rs. 1886.00 respectively. So far 3933 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 2039.95 on 21-Nov-2023 and a 52 week low of Rs. 1240.75 on 22-May-2023. Last one week high and low of the scrip sto...
Mankind Pharma rises on making investment in Actimed Therapeutics
Mankind Pharma rises on making investment in Actimed Therapeutics
Source: Accord Fintech
2023-12-18 10:49:13 am